Form 4: Capricor Therapeutics Executive Granted Stock Options

Karen Krasney, EVP and General Counsel at Capricor Therapeutics, was granted 60,000 stock options on January 2, 2025.

Summary

• Karen Krasney, the EVP and General Counsel of Capricor Therapeutics, was granted 60,000 stock options.
• The options were granted on January 2, 2025, with an exercise price of $14.96 per share.
• The options vest monthly, starting February 1, 2025, over a period of 48 months.
• The options expire on January 2, 2035.
• The options are subject to early exercise, meaning they can be exercised before vesting, but the shares would be restricted and subject to repurchase if employment terminates before vesting.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There are no indications of negative sentiment.

Positives

• The granting of stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Risks

• If the executive leaves the company before the options fully vest, the company has the right to repurchase the shares if they were exercised early.

Industry Context

The granting of stock options is a common practice in the biotechnology industry to incentivize executives and align their interests with the company's long-term success.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for executives in publicly traded companies, particularly in the biotech sector.
• Vesting schedules, such as the 48-month monthly vesting in this case, are typical to encourage long-term commitment.
• The exercise price of $14.96 would be compared to the current market price of the stock to determine the value of the options.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the executive to increase shareholder value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, executive compensation, insider trading, Capricor Therapeutics, equity, vesting